Introduction: current issues in high-dose chemotherapy and stem cell support.

Abstract:

:In the 1980s it became clear that low numbers of primitive hematopoietic cells were present in the peripheral bloodstream. Early clinical trials by investigators in the USA, Australia, and Germany demonstrated that these cells could be collected and reinfused to support high-dose chemotherapy procedures in patients otherwise unable to undergo bone marrow collection, usually because of prior pelvic irradiation. It was, however, difficult to obtain adequate numbers of stem cells from patients in the steady state. It was not until the demonstration by Socinski in Boston and Gianni in Milan that these circulating cells were markedly increased following the administration of either cytokines, chemotherapy, or a combination of both that the use of peripheral blood stem cells over bone marrow began to be widely undertaken. Since that time, peripheral blood stem cell collection has become the preferred means of stem cell support for high-dose chemotherapy because of the reduction in time to neutrophil and platelet engraftment, reduction in the number of transfusions and hospital stay, and an apparent reduction in tumor cell contamination.

journal_name

Bone Marrow Transplant

authors

Shea TC

doi

10.1038/sj.bmt.1701667

subject

Has Abstract

pub_date

1999-05-01 00:00:00

pages

S1-5

eissn

0268-3369

issn

1476-5365

journal_volume

23 Suppl 2

pub_type

杂志文章,评审
  • High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.

    abstract::This retrospective study from the Italian Association of Pediatric Hematology Oncology-Bone Marrow Transplant Group (AIEOP-TMO) reports the results of consolidation with high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with acute myeloid leukemia (AML) in first complet...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.bmt.1703122

    authors: Cesaro S,Meloni G,Messina C,Pillon M,Proglia A,Lanino E,Caniggia M,Bagnulo S,Pession A,Locatelli F,Italian Pediatric Group for Bone Marrow Transplantation.

    更新日期:2001-07-01 00:00:00

  • Low CD4 lymphocyte count in a patient with P. carinii pneumonia after autologous bone marrow transplantation.

    abstract::Authors report a case of P. carinii pneumonia in a child with 5% CD4 lymphocytes (absolute number 5/microliters) after autologous bone marrow transplantation followed by pulmonary irradiation. Serial evaluation of CD4 lymphocyte count or percentage or, at least, detection of significant and persistent lymphopenia coul...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Castagnola E,Dini G,Lanino E,Tasso L,Dallorso S,Garaventa A,Rossi GA,Giacchino R

    更新日期:1995-06-01 00:00:00

  • Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

    abstract::High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980 to 2009, 215 patients aged >1 year with stage 4 N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.75

    authors: Proust-Houdemont S,Pasqualini C,Blanchard P,Dufour C,Benhamou E,Goma G,Semeraro M,Raquin MA,Hartmann O,Valteau-Couanet D

    更新日期:2016-08-01 00:00:00

  • Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?

    abstract::Our purpose was to assess success rates in children of achieving optimal hematopoietic progenitor cells (HPCs) harvest after mobilization with 300 microg/kg pegfilgrastim. Between January 2005 and January 2007, 26 children with solid malignancies who were referred for HPC collection were consecutively included. Hemato...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.412

    authors: Merlin E,Zohar S,Jérôme C,Veyrat-Masson R,Marceau G,Paillard C,Auvrignon A,Le Moine P,Gandemer V,Sapin V,Halle P,Boiret-Dupré N,Chevret S,Deméocq F,Dubray C,Kanold J

    更新日期:2009-06-01 00:00:00

  • Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.

    abstract::Allogeneic hematopoietic stem cell transplantation (SCT) from unaffected donors remains the only modality for the correction of hematological abnormalities in Fanconi anemia (FA) patients. We performed four HLA-matched related donor SCT using a novel irradiation and cyclophosphamide-free conditioning regimen. The prot...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704580

    authors: Maschan AA,Trakhtman PE,Balashov DN,Shipicina IP,Skorobogatova EV,Skvortsova YV,Dyshlevaja ZM,Samochatova EV,Rumiantsev AG

    更新日期:2004-08-01 00:00:00

  • Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.

    abstract::We evaluated a non-radiation containing preparative regimen for persons with myeloma receiving bone marrow (BM) or blood cell transplants. Twenty-three adults with advanced multiple myeloma (15 responsive to chemotherapy, 8 resistant) received cyclophosphamide 120 mg/kg and busulfan 14-16 mg/kg followed by the infusio...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Schiller G,Nimer S,Vescio R,Lieb G,Lee M,Gajewski J,Territo M,Berenson J

    更新日期:1994-07-01 00:00:00

  • Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells.

    abstract::Six patients treated for relapsed chronic myeloid leukaemia after allogeneic bone marrow transplantation with donor buffy coat transfusions were investigated. In the 5 patients who achieved molecular remission high frequencies of host-reactive interleukin 2-secreting T helper cell precursors (Th-p) were detectable by ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bunjes D,Theobald M,Hertenstein B,Wiesneth M,Novotny J,Arnold R,Heimpel H

    更新日期:1995-05-01 00:00:00

  • The role of high-dose chemotherapy with autologous bone marrow transplantation in the treatment of breast cancer.

    abstract::Autologous bone marrow reinfusion rapidly repopulates severely damaged bone marrow thus shortening the period of myelosuppression following high-dose chemotherapy programs. This strategy has been successfully employed in several hematologic malignancies such as acute leukemia, Hodgkin's disease, non-Hodgkin's lymphoma...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Hortobagyi GN

    更新日期:1988-11-01 00:00:00

  • First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.

    abstract::Extragonadal germ cell tumors are classified according to the staging system of the International Germ Cell Cancer Collaborative Group (IGCCCG). The 5-year overall and disease-free survival rates for poor prognosis patients are 41 and 48%, respectively after standard-dose chemotherapy. We report the experience of the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704704

    authors: Rosti G,De Giorgi U,Wandt H,Lioure B,Leyvraz S,Kolbe K,Papiani G,Ballardini M,Kulekci A,Demirer T,Solid Tumours Working Party.

    更新日期:2004-12-01 00:00:00

  • Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?

    abstract::The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703255

    authors: Sweetenham JW

    更新日期:2001-11-01 00:00:00

  • HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome.

    abstract::Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2009.351

    authors: Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X

    更新日期:2010-08-01 00:00:00

  • Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients.

    abstract::Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important and frequent complications relate to the profound immunosuppression that inevitably occurs during th...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703185

    authors: D'Costa S,Slobod KS,Benaim E,Bowman L,Cunningham J,Holladay M,Howlett N,Srivastava DK,Hurwitz JL

    更新日期:2001-09-01 00:00:00

  • Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation.

    abstract::Autologous stem cell transplantation (PBSCT) is standard for young patients in MM and its TRM has decreased after the 2000s. Bortezomib and immunomodulatory agents (IMiDs) in MM have improved the outcome. However, they seem to boost pro-inflammatory stage increasing the incidence of engraftment syndrome (ES). Favorabl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0189-2

    authors: Gutiérrez-García G,Rovira M,Magnano L,Rosiñol L,Bataller A,Suárez-Lledó M,Cibeira MT,de Larrea CF,Garrote M,Jorge S,Moreno A,Rodríguez-Lobato LG,Carreras E,Díaz-Ricart M,Palomo M,Martínez C,Urbano-Ispizua A,Bladé J,Fe

    更新日期:2018-12-01 00:00:00

  • Long-term donor health and its relationship with outcome of allogeneic hematopoietic stem cell transplantation.

    abstract::Data on long-term follow-up of donors for hematopoietic stem cell transplantation (HSCT) are limited. Donors of 612 adult allogeneic HSCT were studied, at a median of 81 (14-181) months post-HSC donation. Nine donors had severe health problems. Five donors died from aggressive malignancies or terminal illness, at a me...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705274

    authors: Au WY,Lie AK,Cheng JW,Liang R,Kwong YL

    更新日期:2006-03-01 00:00:00

  • The number of circulating CD34+ blood cells predicts the colony-forming capacity of leukapheresis products in children.

    abstract::In children, only a few guidelines are available for optimizing peripheral blood progenitor cell (PBPC) harvesting. We analyzed by means of flow cytometry and clonogenic assays 60 harvest products obtained from 20 children by standardized leukapheresis after treatment with chemotherapy and CSF. In addition, 27 fresh b...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Leibundgut K,von Rohr A,Brülhart K,Hirt A,Ischi E,Jeanneret C,Muff J,Ridolfi-Lüthy A,Wagner HP,Tobler A

    更新日期:1995-01-01 00:00:00

  • HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation.

    abstract::HLA-C matching is an important determinant of outcome after myeloablative unrelated donor (URD) hematopoietic stem cell transplantation. However, its importance in non-myeloablative stem cell transplantation (NST) is not known. We report a retrospective analysis of 111 patients who underwent URD NST, of whom 78 were 1...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1705315

    authors: Ho VT,Kim HT,Liney D,Milford E,Gribben J,Cutler C,Lee SJ,Antin JH,Soiffer RJ,Alyea EP

    更新日期:2006-05-01 00:00:00

  • Effects of cryopreservation on subsets of fetal liver cells.

    abstract::Human fetal livers from 6 to 13 weeks postconception were analysed before and after cryopreservation. The percentages of cell subsets, detected by MoAbs, did not change significantly after cryopreservation. Compared with BM, fetal liver contained significantly smaller subsets of cells identified by MoAbs, with two exc...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ek S,Ringdén O,Markling L,Dahlberg N,Pschera H,Seiger A,Sundström E,Westgren M

    更新日期:1993-05-01 00:00:00

  • Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.

    abstract::A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Calderwood S,Doyle JJ,Hitzler JK,Saunders EF,Freedman MH

    更新日期:1996-07-01 00:00:00

  • Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.

    abstract::Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions ad...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705751

    authors: Gurkan E,Patah PA,Saliba RM,Ramos CA,Anderson BS,Champlin R,de Lima M,Lichtiger B

    更新日期:2007-09-01 00:00:00

  • Evaluation of chimerism after bone marrow transplantation with single locus minisatellite DNA probes.

    abstract::The origin of cells in almost all allogeneic donor-recipient pairs can be determined through the use of highly polymorphic minisatellite DNA probes. Single-locus probes were cloned from hypervariable fragments in a human DNA fingerprint detected with a multi-locus probe. While each probe is highly polymorphic and locu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Harano H,Maruta A,Matsuzaki M,Kanamori H,Fukawa H,Noguchi T,Miyashita H,Ogawa K,Motomura S,Kodama F

    更新日期:1993-09-01 00:00:00

  • Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis.

    abstract::Autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated as a therapy for patients with progressive multiple sclerosis (MS) at risk of debilitating neurological impairment. While preliminary results from a few studies have been reported, little is known about toxicities or outcome of HSCT...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703324

    authors: Oyama Y,Cohen B,Traynor A,Brush M,Rodriguez J,Burt RK

    更新日期:2002-01-01 00:00:00

  • Autologous bone marrow transplantation for acute lymphoblastic leukemia.

    abstract::Between December 1979 and February 1991, 89 patients with ALL received autologous BMT. Median patient age was 18.4 years. Ten patients were in first remission, 52 were in second or greater remission and 27 were in relapse at the time of transplant. Conditioning regimens utilized chemotherapy alone (5 patients) or in c...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Doney K,Buckner CD,Fisher L,Petersen FB,Sanders J,Appelbaum FR,Anasetti C,Badger C,Bensinger W,Deeg HJ

    更新日期:1993-10-01 00:00:00

  • Safety and efficacy of fresh whole blood donor lymphocyte infusion in children.

    abstract::Donor lymphocyte infusion (DLI) is a form of cellular immunotherapy which is known to be effective in preventing relapse in leukemia by inducing graft versus leukemia (GVL) effect. In hematopoietic stem cell transplantation (HSCT) for benign hematological conditions including primary immune deficiency, mixed chimerism...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/s41409-019-0580-7

    authors: Swaminathan VV,Uppuluri R,Patel S,Sivashankaran M,Ravichandran N,Ramanan KM,Ramakrishnan B,Vaidhyanathan L,Raj R

    更新日期:2019-11-01 00:00:00

  • Clonality studies in patients undergoing allogeneic and autologous bone marrow transplantation for haematological malignancies.

    abstract::Twenty three allogeneic bone marrow transplant (BMT) patients with female donors and 23 female autologous transplant patients were assessed for clonality status after transplant to determine the nature of haemopoietic reconstitution. The X chromosome probes PGK, HPRT and M27 beta were used to assess clonality by analy...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Saunders MJ,Jowitt SN,Yin JA

    更新日期:1995-01-01 00:00:00

  • Evaluation of optimal survival of primitive progenitor cells (LTC-IC) from PBPC apheresis products after overnight storage.

    abstract::Optimal overnight (ON) storage of PBPC aphereses is becoming an increasingly important issue and different options for storing PBPC products exist. The survival of primitive progenitor cells is of major interest, as recent data suggest that these progenitors are not only important for long-term engraftment but also co...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702104

    authors: Petzer AL,Gunsilius E,Zech N,Clausen J,Hoflehner E,Nussbaumer W,Gastl G

    更新日期:2000-01-01 00:00:00

  • Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation.

    abstract::Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has proven effective in adult T-cell leukemia/lymphoma (ATL) patients. To study the graft-versus-ATL (Gv-ATL) effects after allo-HSCT, we analyzed 21 ATL patients who had been treated at our hospital. Of these, 18 had acute-, 2 had lymphoma- and 1 had chro...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.39

    authors: Yonekura K,Utsunomiya A,Takatsuka Y,Takeuchi S,Tashiro Y,Kanzaki T,Kanekura T

    更新日期:2008-06-01 00:00:00

  • CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation.

    abstract::The aim of this study was to define factors that significantly influence the early kinetics of donor chimerism after transplantation. In a retrospective study, the percentage of donor chimerism in peripheral blood measured with sex-chromosome-specific probes and fluorescence-in situ hybridization was analyzed in 184 r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704710

    authors: Mohr B,Koch R,Thiede C,Kroschinsky F,Ehninger G,Bornhäuser M

    更新日期:2004-12-01 00:00:00

  • Alternative donor transplant of benign primary hematologic disorders.

    abstract::Hematopoietic SCT is currently the only curative therapy for a range of benign inherited and acquired primary hematologic disorders in children, including BM failure syndromes and hemoglobinopathies. The preferred HLA-matched sibling donor is available for only about 25% of such children. However, there has been subst...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.1

    authors: Tolar J,Sodani P,Symons H

    更新日期:2015-05-01 00:00:00

  • Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.

    abstract::Four patients with acute myeloid leukaemia relapsed within 6 months of allogeneic BMT. Three patients were treated with cytosine arabinoside and amsacrine while the fourth received no chemotherapy. All patients received infusions of leucocytes obtained by repeated leukapheresis from the original bone marrow donor. Thr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Szer J,Grigg AP,Phillips GL,Sheridan WP

    更新日期:1993-02-01 00:00:00

  • Pulmonary infection with microsporidia after allogeneic bone marrow transplantation.

    abstract::Microsporidia are obligate, intracellular protozoal parasites that can be pathogenic in immunocompromised individuals. The majority of cases of microsporidiosis have been documented in patients with HIV, and only a few case reports exist of infection in solid organ transplant patients. We report the first case of pulm...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704327

    authors: Teachey DT,Russo P,Orenstein JM,Didier ES,Bowers C,Bunin N

    更新日期:2004-02-01 00:00:00